Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelinesNear total body vitiligo secondary to immunotherapy for metastatic melanoma
Olamiju B, Leventhal J. Near total body vitiligo secondary to immunotherapy for metastatic melanoma. British Journal Of Dermatology 2020, 183: e2-e2. PMID: 32147813, DOI: 10.1111/bjd.18944.Peer-Reviewed Case Reports and Technical Notes